Cancer clinical trials in the region Auvergne-Rhône-Alpes
494 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Endometrial cancer
#NCT04590326
Cohortes endomètre
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2
Endometrial cancer
#NCT03564340
#2024-510783-23-00
Cohortes endomètre
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT03564340
#2024-510783-23-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2
Lymphoma
#NCT05607420
#2022-501607-27-00
Partie escalade de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Primary mediastinal lymphoma
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
MALT lymphoma
Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2
Lymphoma
#NCT05607420
#2022-501607-27-00
Partie extension de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Follicular lymphoma
Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2
Lymphoma
#NCT06495723
#2023-509648-88-00
Escalade et extension de dose
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Xenothera SAS
Phase 1 / Phase 2
Lung cancer
#NCT06362252
#2023-509629-36-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2
Colon cancer
Rectal cancer
#NCT06923761
#2023-504845-30-00
Module 2 Partie D cancer colorectal pMMR/MSS
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2
Lung cancer
#NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT05118789
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.